Lopinavir: Clinical Trials

51 trials of Lopinavir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

35 completed, 8 terminated, 8 unknown. 51 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 451Completed 35, Terminated 8, Unknown 8

Follow Lopinavir: new trials by email Literature Review of Lopinavir trials Research Report on Lopinavir

Trials (filtered) newest first · largest first

All 51 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparison of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients
Remdesivir, Lopinavir/ Ritonavir and Remdesivir combination - Covid19
Phase 4UnknownAhmed Essam902020-11-012021-03-17
Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.
Remdesivir, Hydroxychloroquine, Tocilizumab - Covid19, Pneumonia
Phase 4UnknownOctober 6 University1502020-10-012021-03-17
Interferon Beta 1a in Hospitalized COVID-19 Patients
Interferon Beta-1A, Lopinavir / Ritonavir, Single Dose of Hydroxychloroquine - COVID-19
Phase 4UnknownShahid Beheshti University of Medical Sciences402020-04-152020-04-20
Umifenovir in Hospitalized COVID-19 Patients
Umifenovir, Interferon-β 1a, Lopinavir / Ritonavir - COVID-19
Phase 4UnknownShahid Beheshti University of Medical Sciences402020-04-152020-04-20
The Clinical Study of Carrimycin on Treatment Patients With COVID-19
Carrimycin, lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate, basic treatment - Novel Coronavirus Infectious Disease (COVID-19)
Phase 4UnknownBeijing YouAn Hospital5202020-02-232020-02-27
A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
Abidol hydrochloride, Oseltamivir, Lopinavir/ritonavir - 2019-nCoV
Phase 4UnknownTongji Hospital4002020-02-012020-03-17
The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection
Lopinavir and Ritonavir Tablets, Arbidol - Coronavirus Infections
Phase 4CompletedGuangzhou 8th People's Hospital862020-01-282020-07-01
Antiretroviral Regime for Viral Eradication in Newborns
Zidovudine, Nevirapine, Lamivudine - HIV/AIDS and Infections
Phase 4CompletedNational Center for Women and Children's Health, China CDC6002016-04-012022-09-28
IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children
ZDV+3TC+LPV/r - HIV Positive, Malnourished
Phase 4CompletedInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group522015-10-262021-08-12
HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen
Dolutegravir, PI, 2 NRTI - HIV-1
Phase 4CompletedHospital Universitari Vall d'Hebron Research Institute442015-06-012017-06-14
Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB
lopinavir with ritonavir in 1:1 ratio, Lopinavir/ritonavir 4:1 - Acquired Immunodeficiency Syndrome, Tuberculosis
Phase 4CompletedDrugs for Neglected Diseases962013-01-012017-05-11
Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)
8 hourly LPV/r during TB treatment, Nevirapine, Lopinavir/Ritonavir - Tuberculosis, HIV
Phase 4CompletedUniversity of Cape Town2002012-11-012017-10-27
MARCH Renal Substudy
arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors, Arm 2 boosted protease inhibitors and maraviroc, Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc - Proteinuria, HIV
Phase 4CompletedKirby Institute762012-06-012016-01-20
Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily
Lopinavir/ritonavir 800 mg / 200mg - HIV
Phase 4CompletedDaniel Podzamczer212012-05-012016-10-06
Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy
Lumbar puncture (Lopinavir/ritonavir monotherapy), Lumbar puncture (HAART: Lopinavir/ritonavir + 2 NRTI) - HIV
Phase 4CompletedGermans Trias i Pujol Hospital352010-08-012019-12-05
Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)
lopinavir/ritonavir plus maraviroc - HIV Infections
Phase 4TerminatedTemple University12010-04-012020-11-02
Bone and Body Comp: A Sub Study of the SECOND-LINE Study
Lopinavir / ritonavir, 2-3N(t)RTI, raltegravir - HIV
Phase 4CompletedKirby Institute2102010-02-012025-06-26
Drug-Drug Interaction of Lopinavir/Ritonavir on Pitavastatin
Pitavastatin (NK-104), Lopinavir/ritonavir - Healthy Volunteers
Phase 4CompletedKowa Research Institute, Inc.242010-01-012021-06-22
Pilot Assessment of Lopinavir/Ritonavir and Maraviroc
lopinavir/ritonavir plus maraviroc - HIV Infections, Acquired Immunodeficiency Syndrome
Phase 4TerminatedRodwick, Barry M., M.D.32009-12-012015-06-23
Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens
Darunavir/ritonavir, Lopinavir/ritonavir - HIV Infections
Phase 4CompletedGermans Trias i Pujol Hospital732009-10-012014-02-13

Showing 20 of 51. Sign in to see all of them.

Conditions studied

HIV Infections (27)  ·  Acquired Immunodeficiency Syndrome (11)  ·  COVID-19 (5)  ·  Tuberculosis (3)  ·  Lipodystrophy (2)  ·  AIDS-Related Opportunistic Infections (1)  ·  Breast Feeding (1)  ·  Cardiovascular Diseases (1)  ·  Coronavirus Infections (1)  ·  Disease Progression (1)  ·  Dyslipidemias (1)  ·  Glucose Metabolism Disorders (1)  ·  HIV Seropositivity (1)  ·  HIV-Associated Lipodystrophy Syndrome (1)  ·  Hepatitis C (1)

Sponsors

Germans Trias i Pujol Hospital (3)  ·  Kirby Institute (3)  ·  AbbVie (prior sponsor, Abbott) (2)  ·  Fundacion SEIMC-GESIDA (2)  ·  Juan A. Arnaiz (2)  ·  Oswaldo Cruz Foundation (2)  ·  Shahid Beheshti University of Medical Sciences (2)  ·  Abbott (1)  ·  Ahmed Essam (1)  ·  Allina Health System (1)  ·  Amsterdam UMC, location VUmc (1)  ·  Beijing YouAn Hospital (1)  ·  Daniel Podzamczer (1)  ·  Drugs for Neglected Diseases (1)  ·  Emory University (1)

Countries

United States (15)  ·  Spain (11)  ·  South Africa (5)  ·  Argentina (3)  ·  Canada (3)  ·  China (3)  ·  Mexico (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Brazil (2)  ·  Egypt (2)  ·  Iran (2)  ·  Malawi (2)  ·  Puerto Rico (2)  ·  Thailand (2)

Top investigators

Ilad Alavi Darazam, MD (2)  ·  Minoosh Shabani, MD (2)  ·  Mohammadreza Haji Esmaelie, MD (2)  ·  Seyed Sina Naghibi Irvani, MD, MPH, MBA (2)  ·  Shervin Shokouhi, MD (2)  ·  Allan R. Tenorio, M.D. (1)  ·  Andrew D Carr, MD (1)  ·  Andrew R. Zolopa, MD (1)  ·  Andrew Ratsela, MD (1)  ·  Barry M. Rodwick, M. D. (1)  ·  Beatriz J Grinsztejn, MD (1)  ·  Brookie Best, PharmD, MAS (1)  ·  Carl J Fichtenbaum, MD (1)  ·  Carlos R Rivera-Vazquez, MD (1)  ·  Daniel Podzamczer, MD (1)

Results publications

PMID 37988391, PMID 19275490, PMID 19424051, PMID 19440326, PMID 19479079, PMID 19898246, PMID 19906626, PMID 19967342, PMID 20455766, PMID 20617176, PMID 20942650, PMID 21054216, PMID 21126955, PMID 21716078, PMID 21886816, PMID 22364141, PMID 22448211, PMID 22627182, PMID 23383047, PMID 23386261, PMID 23921615, PMID 24204757, PMID 24614377, PMID 25155608, PMID 25386736, PMID 25831464, PMID 26810651, PMID 27815068, PMID 29683854, PMID 30529029, PMID 31081020, PMID 32071055, PMID 32838353, PMID 33464021, PMID 34273635, PMID 34764044, PMID 37919816

NIH funding

2008 (1), U01AI068632 (1)